Genmab A/S (GMAB) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Genmab A/S, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track GMAB live on Mooboard →

Later20

  • Feb 2027
    Genmab A/S(GMAB)Phase 2/3 readout
    Rina-S · Phase 3 · Platinum-resistant Ovarian Cancer
    NCT06619236: Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer. Primary completion 2027-02 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 2027
    Genmab A/S(GMAB)Phase 2/3 readout
    Epcoritamab · Phase 2 · Diffuse Large B-Cell Lymphoma; Classic Follicular Lymphoma
    NCT05451810: A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma. Primary completion 2027-03 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 2027
    Genmab A/S(GMAB)Phase 2/3 readout
    Epcoritamab · Phase 3 · Diffuse Large B-Cell Lymphoma
    NCT05578976: A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL). Primary completion 2027-06 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 2027
    Genmab A/S(GMAB)Phase 2/3 readout
    Rina-S · Phase 1 / Phase 2 · High Grade Epithelial Ovarian Cancer; High Grade Serous Ovarian Cancer
    NCT05579366: Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001). Primary completion 2027-07 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 30, 2027
    Genmab A/S(GMAB)Phase 2/3 readout
    Acasunlimab · Phase 3 · PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
    NCT06635824: Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06). Primary completion 2027-07-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 2027
    Genmab A/S(GMAB)Phase 2/3 readout
    Rina-S · Phase 3 · Platinum-resistant Ovarian Cancer
    NCT07604766: An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China. Primary completion 2027-09 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 2027
    Genmab A/S(GMAB)Phase 2/3 readout
    Epcoritamab (monotherapy) · Phase 1 / Phase 2 · Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma
    NCT04542824: Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL). Primary completion 2027-09 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 30, 2027
    Genmab A/S(GMAB)Phase 2/3 readout
    rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone · Phase 1 / Phase 2 · Diffuse Large B-Cell Lymphoma; Follicular Lymphoma
    NCT04663347: Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL). Primary completion 2027-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 22, 2027
    Genmab A/S(GMAB)Phase 2/3 readout
    Rina-S · Phase 2 · Non-small Cell Lung Cancer (NSCLC)
    NCT07288177: Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer. Primary completion 2027-11-22 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 2027
    Genmab A/S(GMAB)Phase 2/3 readout
    Epcoritamab · Phase 1 / Phase 2 · Relapsed/Refractory Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    NCT04623541: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome. Primary completion 2027-12 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 2028
    Genmab A/S(GMAB)Phase 2/3 readout
    Epcoritamab · Phase 3 · Diffuse Large B-Cell Lymphoma
    NCT06508658: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Primary completion 2028-03 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 2028
    Genmab A/S(GMAB)Phase 2/3 readout
    Rina-S · Phase 2 · Gastrointestinal Cancers
    NCT07539311: Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers. Primary completion 2028-09 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 2028
    Genmab A/S(GMAB)Phase 2/3 readout
    Rina-S · Phase 3 · Ovarian Cancer; Platinum-sensitive Ovarian Cancer
    NCT07225270: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy. Primary completion 2028-10 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 2029
    Genmab A/S(GMAB)Phase 2/3 readout
    Epcoritamab · Phase 1 / Phase 2 · DLBCL; High-grade B-cell Lymphoma (HGBCL)
    NCT03625037: First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. Primary completion 2029-01 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 2029
    Genmab A/S(GMAB)Phase 2/3 readout
    Petosemtamab · Phase 3 · Left-sided Colorectal Cancer
    NCT07702032: Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer. Primary completion 2029-07 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Aug 2029
    Genmab A/S(GMAB)Phase 2/3 readout
    Rina-S · Phase 3 · Endometrial Cancer; Recurrent or Progressive Endometrial Cancer
    NCT07166094: Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer. Primary completion 2029-08 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 2029
    Genmab A/S(GMAB)Phase 2/3 readout
    Rina-S · Phase 3 · Platinum-Sensitive Ovarian Cancer; Ovarian Cancer
    NCT07564141: Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer. Primary completion 2029-12 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 2029
    Genmab A/S(GMAB)Phase 2/3 readout
    Epcoritamab · Phase 3 · Follicular Lymphoma (FL)
    NCT05409066: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma. Primary completion 2029-12 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 2032
    Genmab A/S(GMAB)Phase 2/3 readout
    Epcoritamab · Phase 2 · Non-Hodgkin Lymphoma
    NCT05283720: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma. Primary completion 2032-11 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 2037
    Genmab A/S(GMAB)Phase 2/3 readout
    Epcoritamab · Phase 3 · Follicular Lymphoma (FL)
    NCT06191744: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma. Primary completion 2037-11 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

How Genmab A/S has moved — past-year price reactions

How binary is GMAB? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

1.2%
typical day (1Y)
0
±10% days
33.6%
annualized vol
250
trading days
Largest single-day moves
  • -7.9%2025-10-20no matched headline
  • -6.7%2026-03-03no matched headline
  • -6.3%2026-06-02no matched headline
  • +6%2026-05-20no matched headline
  • +5.6%2026-06-30no matched headline
  • +5.2%2026-01-21no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

Genmab A/S — active clinical pipeline

Genmab A/S's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

11 assets27 programsPh1 6Ph2 13Ph3 8
AreasOncologyOther
EpcoritamabOncology · CD20×CD3
Phase 1
Non-hodgkin Lymphoma
Phase 2
B-Cell Non-Hodgkin LymphomaDiffuse Large B-Cell LymphomaDLBCLNon-Hodgkin LymphomaRelapsed/Refractory Chronic Lymphocytic Leukemia
Phase 3
Diffuse Large B-Cell Lymphoma (4)Follicular Lymphoma (FL) (2)
Rina-SOncology
Phase 2
Gastrointestinal CancersHigh Grade Epithelial Ovarian CancerNon-small Cell Lung Cancer (NSCLC)
Phase 3
Endometrial CancerOvarian CancerPlatinum-resistant Ovarian Cancer (2)Platinum-Sensitive Ovarian Cancer
AcasunlimabOncology
Phase 2
Non Small Cell Lung Cancer MetastaticSolid Tumors
Phase 3
PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
PetosemtamabOncology
Phase 3
Left-sided Colorectal Cancer
GEN1042Oncology
Phase 1
Malignant Solid Tumor
Phase 2
Malignant Solid Tumor
Epcoritamab (monotherapy)Oncology · CD20×CD3
Phase 2
Diffuse Large B Cell Lymphoma
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisoneOncology
Phase 2
Diffuse Large B-Cell Lymphoma
GEN1079Oncology
Phase 1
Advanced Solid Tumors
GEN1106Oncology
Phase 1
Solid Tumors
GEN1119Oncology
Phase 1
Solid Tumours
GEN3018Other
Phase 1
R/R AML

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

See the full biopharma catalyst calendar across all covered companies.